BioStem Technologies, Inc. (OTC: BSEM) Appoints New Members to Its Board of Directors

March 18, 2016

OAKLAND PARK, FL--(Marketwired - Mar 18, 2016) - BioStem Technologies, Inc. (OTC PINK: BSEM) today announced it has appointed Robert Watson, Henry VanVurst and Andrew VanVurst to its Board of Directors. Watson is a veteran corporate executive and strategist of the Biotech, Pharmaceutical and Financial sectors. The appointment of these new board members was made effective March 17, 2016.


Since 1998, Robert Watson has been developing and executing corporate strategy that increases the value of early stage companies. He is best known for creating and executing scalable and effective funding programs, but he has also developed and led hundreds of complex strategic maneuvers that increased shareholder value for his client companies, including capital structuring, strategy development, strategic partnerships, mergers, acquisitions, turnarounds, business model transitions, executive recruitments, market repositioning's, sales strategy changes, startups and spinoffs. He can quickly identify root causes of mission critical corporate problems (including difficulties in fundraising), and develop and execute the strategy necessary to overcome those problems.

BioStem Technologies, Inc. is confident the acquisition of these new members of the Board will allow for a rapid expansion into new and developing sectors. With the expertise, background and knowledge of these individuals from different sectors BioStem will continue to grow and enhance its operations.


About BioStem Technologies, Inc. (OTC:BSEM):
BioStem Technologies (OTC: BSEM) is engaged in the advancement of regenerative medicine and antiaging strategies throughout the United States, Europe and Mexico. Our goal is to deliver the highest standard wellness and stem cell products that are backed by science. Through scientific studies, we seek to become a world leader in the wellness arena. This will be accomplished by using high quality nutraceuticals and stem cells. Our state-of-the-art laboratory is the first significant step in our quest to introduce the world and our shareholders to our dedication to you and your well-being. 


Mission Statement- BioStem Technologies, Inc. is a Global Leader in Anti-Aging research. We are focused on advancing your quality of life, health span and wellness.


Vision Statement- BioStem Technologies, Inc. is a group of scientists, physicians, and visionaries creating the possibility of living life to its fullest. Our products and strategies are dedicated to helping you live your best, feel your best, and be your best.


Forward-Looking Statements Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.


Share on Facebook
Share on Twitter
Please reload

Featured Posts

BioStem Technologies Releases Third Quarter 2018 Shareholder Update

December 10, 2018

Please reload

Recent Posts
Please reload